过敏原特异性免疫治疗（AIT）是通过长期、反复给予患者特定过敏原，诱导机体建立免疫耐受，从而改变过敏性疾病自然病程的唯一“对因治疗”手段。随着过敏性疾病患病率的持续攀升、患者对AIT疗法的认知加深，以及分子过敏原、重组过敏原等新一代技术的快速突破，AIT正迎来从“经验性治疗”向“精准免疫调节”跨越的关键发展期。
在此背景下，弗若斯特沙利文（简称"沙利文"）撰写了《2026年全球过敏原特异性免疫治疗行业发展蓝皮书》（以下简称"蓝皮书"）。蓝皮书旨在对过敏原特异性免疫治疗领域进行深入分析，从过敏性疾病流行病学、过敏原类型与致敏机制、AIT技术演进、给药路径迭代、临床未满足需求及未来发展趋势等多维度进行全面阐述，追踪行业和技术发展脉络，挖掘行业发展巨大潜力，分析市场发展背后的驱动因素。
Allergen specific immunotherapy (AIT) is the only "causative treatment" that alters the natural course of allergic diseases by inducing immunological tolerance through long-term, repeated administration of specific allergens to patients. Amid the continuously rising prevalence of allergic diseases, patients' growing awareness of AIT, and rapid breakthroughs in next-generation technologies such as molecular allergens and recombinant allergens, AIT is entering a critical development phase, transitioning from "empirical treatment" to "precise immunomodulation."
Against this backdrop, Frost & Sullivan has prepared the 2026 Global Allergen Specific Immunotherapy Development Blue Book, which provides an in-depth analysis of the field of allergen specific immunotherapy, offering a comprehensive exposition from multiple perspectives, including the epidemiology of allergic diseases, types of allergens and sensitization mechanisms, the evolution of AIT technologies, iterations of administration routes, unmet clinical needs, and future development trends. It traces the technological and developmental trajectory of the industry, explores its significant potential, and analyzes the driving factors behind market growth.
